孙善芳,袁红建,潘怀富

• 1:姜堰市人民医院血液科

摘要(Abstract)：

目的:观察高三尖杉酯碱(HHT)、阿糖胞苷(Ara-C)和粒细胞集落刺激因子(G-CSF)联合方案(HAG方案)治疗中高危骨髓增生异常综合征(MDS)以及低增生髓系白血病(AML)的临床疗效。方法:应用HAG方案治疗MDS 6例和AML 12例,1个疗程诱导治疗失败后继用1个疗程治疗,观察治疗的效果及不良反应。结果:6例MDS完全缓解(CR)4例,部分缓解(PR)1例,总有效率83.3%;12例AML患者CR 6例,PR 2例,总有效率66.6%;大部分患者出现了可以耐受的不良反应,主要表现为骨髓抑制。结论:HAG治疗中、高危MDS以及低增生AML近期疗效显著,不良反应轻。

关键词(KeyWords)： 骨髓增生异常综合征;白血病,髓样;三尖杉酯碱;阿糖胞苷;粒细胞集落刺激因子

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 孙善芳,袁红建,潘怀富

DOI: 10.19367/j.cnki.1000-2707.2011.06.035

参考文献(References)：

• [1]Fu Kumoto J S,Greenberg P L.Management of patientswith higher risk myelodysplastic syndromes[J].Crit RevOncol Hematol,2005(56):179-192.
• [2]DeWitteT,MuusP,DePauwB,etal.Intensive antileukemictreatment of patients younger than 65 years with myelodys-plastic syndromes and secondary acute myelogenous leuke-mia[J].Cancer,1990(66):831-837.
• [3]叶任高,陆再英.内科学[M].6版.北京:人民卫生出版社,2004:597-599.
• [4]宋善俊,陈燕威廉姆斯血液学[M].北京:人民卫生出版社,2004:1104.
• [5]张之南,沈悌.血液病诊断及疗效标准[M].3版.北京:科学出版社,2007:122-123.
• [6]Cheson BD,Greenberg PL,Bennett JM,et al.Clinicalapplication an proposal for modification of the internation-al working group response criteria in myelodysplasia[J].Blood,2006(108):419-425.
• [7]吴小津,吴德沛,孙爱宁,等.预激方案诱导治疗老年性急性髓系白血病的疗效观察[J].中华内科杂志,2004(12):936-937.
• [8]Saito K,Nakamaura Y,Aoyagi M,et al.Low dose cytara-bine and aclarubcinin combination with granulocyte colonystimulating factor(CAGregimen)for previously treated pa-tients with replapsed or primary resistant acute myeloge-nous leukemia and previously untreated elderly patientswith AML,secondary AML,and refractory anima with ex-cess blastsin transformation[J].IntJHematol,2000(3):238-244.
• [9]Lowenberg B,Van Putten W,Theobald M,et al.Effect ofpriming with granulocyte colony stimulating factor on theoutcome of chemotherapy for acute myeloid leukemia[J].NEnglJMed,2003(349):743-752.
• [10]Cheson B D,Bennett J M,Kantarijian H,et al.Report ofaninter national working group to standardize response cri-teria for myelodysplastic syndromes[J].Blood,2000(96):3671-3674.

文章评论(Comment)：